ArticleCancer chemotherapy and pharmacology2024

Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19.

Ming Chang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.